4 Reasons Amarin Stock Could Tumble Even Further
Amarin (NASDAQ: AMRN) investors who had been expecting a sales explosion have instead seen the bottom fall out from under their shares, and the company's second-quarter earnings report was less than encouraging. Although the biotech's stock price has already given up 68% in 2020, management recently gave us four reasons to expect further disappointment.
The only product Amarin has on the market, Vascepa, is a fish oil supplement that's approved for use in combination with statins to reduce the risk of heart attacks. While there are millions of potential Vascepa customers already on statins in the U.S., those patients could end up with more inexpensive treatment options than previously expected. An unfavorable ruling in favor of generic drugmakers seeking to market their own FDA-approved formulations of Vascepa already appears to be having a negative effect on its sales growth.
Image source: Getty Images.
Source Fool.com
